Novel treatment of cisplatin-resistant cancer with OGG1 inhibitors
| Reference number | |
| Coordinator | Karolinska Institutet - Institutionen för medicinsk biokemi och biofysik |
| Funding from Vinnova | SEK 1 999 998 |
| Project duration | September 2015 - August 2017 |
| Status | Completed |
Purpose and goal
The aim of our project was to develop a novel treatment for resistant cancer. Through the development of more potent and selective compounds, we were able to broaden the scope of our project. Overall, we completed most of the activities we had originally planned and are now in a position to choose a clinical candidate drug for preclinical development.
Expected results and effects
During the course of this project we have validated our OGG1 inhibitors as a potential new therapy not only for resistant cancer, but also for other indications with an estimated >1 billion people who could benefit from our product once it’s fully developed. We will now select a clinical candidate for preclinical development and we expect to make a difference for people suffering from a wide range of diseases including many types of cancer.
Planned approach and implementation
Our multidisciplinary research approach has successfully enabled us to validate and further develop our OGG1 inhibitors as a potential therapy for cancer and other diseases. By combining expertise in cell biology, biochemistry, structural biology, medicinal chemistry and drug development from three Swedish universities and by establishing a new research collaboration with international universities we now have a product that could be useful for treating a wide variety of diseases including cancer.